Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape
Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
J Therriault, SE Schindler, G Salvadó… - Nature Reviews …, 2024 - nature.com
Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …
Comparison of immunoassay-with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology
Background Antibody-based immunoassays have enabled quantification of very low
concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF) …
concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF) …
[HTML][HTML] Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology
J Therriault, NJ Ashton, I Pola, G Triana-Baltzer… - …, 2024 - thelancet.com
Background Blood-based biomarkers of Alzheimer's disease (AD) have become
increasingly important as scalable tools for diagnosis and determining clinical trial eligibility …
increasingly important as scalable tools for diagnosis and determining clinical trial eligibility …
Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology
PR Kac, F González-Ortiz, A Emeršič… - Nature …, 2024 - nature.com
Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations
with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p …
with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p …
A multiplexed urinary biomarker panel has potential for Alzheimer's disease diagnosis using targeted proteomics and machine learning
J Hällqvist, RC Pinto, WE Heywood, J Cordey… - International Journal of …, 2023 - mdpi.com
As disease-modifying therapies are now available for Alzheimer's disease (AD), accessible,
accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to …
accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to …
[HTML][HTML] Choriocapillaris and retinal vascular alterations in presymptomatic Alzheimer's disease
G Corradetti, D Oncel, S Kadomoto… - … & Visual Science, 2024 - jov.arvojournals.org
Purpose: To compare optical coherence tomography angiography (OCTA) retina metrics
between cognitively healthy subjects with pathological versus normal cerebrospinal fluid …
between cognitively healthy subjects with pathological versus normal cerebrospinal fluid …
A critical appraisal of blood-based biomarkers for Alzheimer's disease
Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …